• Epidemiology and risk factors
• 30 min
  1. Epidemiology of COPD

  • Dr. David Mannino
• 36 min
  2. COPD in never smokers

  • Dr. Sundeep Salvi
• 43 min
  3. Genetics of chronic obstructive pulmonary disease (COPD)

  • Prof. Martin Tobin
• Phenotypes of COPD
• 44 min
  4. COPD and asthma: similarities and differences

  • Prof. Peter Barnes
• Pathophysiology and mechanisms of COPD
• 43 min
  5. The pathology of chronic obstructive pulmonary disease

  • Prof. James Hogg
• 63 min
  6. The continuum of COPD: a physiological perspective

  • Prof. Denis O'Donnell
• 47 min
  7. Inflammatory and immune mechanisms in COPD

  • Prof. Peter Barnes
• 44 min
  8. Mechanisms of COPD exacerbations and relation to exacerbation therapy

  • Prof. Wisia Wedzicha
• 39 min
  9. Protease-antiprotease balance

  • Prof. Robert Stockley
• Therapy and management
• 42 min
  10. Updates in chronic obstructive pulmonary disease (COPD)

  • Dr. Omar S. Usmani
• 45 min
  11. Long-acting bronchodilators in COPD

  • Prof. Bart Celli
• 54 min
  12. Treatment of COPD exacerbations

  • Prof. Antonio Anzueto
• 25 min
  13. Pulmonary rehabilitation: history, promise and problems

  • Prof. Richard Casaburi
• 29 min
  14. Lung volume reduction: advances in COPD

  • Dr. Nick Hopkinson
• 35 min
  15. New pharmacological therapies for COPD

  • Prof. Peter Barnes
• 32 min
  16. The Salford lung study in COPD

  • Dr. Dave Leather
• COPD case studies
• 11 min
  17. COPD treatment case I: COPD with “bronchitis attacks”

  • Dr. Janwillem Kocks
• 13 min
  18. COPD treatment case II: COPD with asthma as child

  • Dr. Janwillem Kocks
• 12 min
  19. COPD treatment case III: COPD with pre-diabetes

  • Dr. Janwillem Kocks
• 48 min
  20. Tailoring care for advanced COPD

  • Prof. Wissam Chatila
• Archived Lectures *These may not cover the latest advances in the field
• 59 min
  21. Alpha-1 antitrypsin deficiency: state of the art

  • Dr. Jamie Stoller
• 34 min
  22. Oxidative stress in COPD

  • Prof. William MacNee
• 24 min
  23. Managing co-morbidity in COPD

  • Dr. John Hurst
• 40 min
  24. Clinical phenotypes of COPD

  • Prof. Jørgen Vestbo
• 27 min
  25. Pulmonary rehabilitation: focusing on rehabilitative exercise

  • Prof. Richard Casaburi
• 36 min
  26. Genetics of COPD

  • Prof. Ian Hall

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Pathology of COPD
3. Air trapping in COPD
4. New bronchodilators
5. Human small airways: beta2-agonists
6. Indacterol vs. salmeterol in COPD
7. LABA+LAMA combination in COPD
8. Unmet needs in COPD
9. Cellular mechanisms of COPD
10. Treating inflammation in COPD
11. Anti-TNF-alpha in COPD
12. Chemokine receptor antagonists in COPD
13. CXCR2 antagonist in COPD
14. Elastase activity of macrophages in COPD
15. Effect of MMP9 inhibitor on emphysema
16. Broad spectrum anti-inflammatory treatment
17. PDE4 inhibitors in COPD
18. Effect of roflumilast in COPD
19. PDE4 inhibitors: side effects
20. Inhaled PDE inhibitors for COPD
21. p38 MAP kinase inhibitors
22. p38 MAP kinase inhibitors in COPD
23. Major barrier to effective treatment of COPD
24. Amplification and steroid resistance
25. Corticosteroids resistance in COPD
26. Theophylline as HDAC activator
27. How does theophylline restore HDAC?
28. Reversal of corticosteroid resistance
29. Nrf2 and antioxidant gene regulation
30. Sulforaphane increases HDAC2 activity
31. New drugs for COPD

Topics Covered

• New treatments for COPD include long-acting bronchodilators and combinations
• Mediator antagonists, including chemokine antagonists
• Broad-spectrum anti-inflammatory treatments
• Reversal of corticosteroid resistance by increasing HDAC2

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on July 31, 2012

Financial Disclosures

• Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.